REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH): auditor change — Reviva Pharmaceuticals appoints Moss Adams as new auditor after Armanino's exit

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Audit Committee appointed Moss Adams LLP as independent accountant for fiscal year ending Dec 31, 2023 on Oct 4, 2023.
Armanino LLP declines reappointment due to transition away from public company audits; notified company on July 18, 2023.
Armanino's audit reports for 2021 and 2022 contained no adverse opinions; 2022 report included a going concern paragraph.
No disagreements or reportable events occurred during Armanino's tenure through Oct 4, 2023.
Armanino remains engaged to complete review of Q3 2023 unaudited financial statements.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. engaged Moss Adams LLP as its auditor.

Action: engagement
Auditor: Moss Adams LLP

Exact text from the filing

sion (the “SEC”) on July 24, 2023, the Company was informed on July 18, 2023 by Armanino LLP (“Armanino”), the Company’s current independent registered public accounting firm, that Armanino would decline to stand for re-appointment after completion of Armanino’s review procedures on the unaudited financial statements of the Company as of and for the three and nine months ended September 30, 2023. Armanino advised the Company that its decision not to stand for reappointment was due to Armanino’s transition away from providing financial statement audit services to public companies. In light of Armanino’s determination, the Audit Committee of the Company’s Board of Directors initiated a process to select a new accounting firm to serve as the Company’s independent registered public accountant. On October 4, 2023, the Audit Committee of the Company’s Board of Directors appointed Moss Adams LL

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

REVIVA PHARMACEUTICALS HOLDINGS, INC. dismissed Armanino LLP as its auditor.

Action: dismissal
Auditor: Armanino LLP

Exact text from the filing

(the “Company”) in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 24, 2023, the Company was informed on July 18, 2023 by Armanino LLP (“Armanino”), the Company’s current independent registered public accounting firm, that Armanino would decline to stand for re-appointment after completion of Armanino’s review procedures on the unaudited financial statements of the Company as of and for the three and nine months ended September 30, 2023. Armanino advised the Company that its decision not to stand for reappointment was due to Armanino’s transition away from providing financial statement audit services to public companies. In light of Armanino’s determination, the Audit Committee of the Company’s Board of Directors initiated a process to select a new accounting firm to serve as the Company’s independent registered public accountant.

View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

REVIVA PHARMACEUTICALS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-027674

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.